Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2011 by Drugs for Neglected Diseases.
Recruitment status was Recruiting

Sponsor:

Collaborators:

Gilead Sciences

Paladin Laboratories Inc

Information provided by:

Drugs for Neglected Diseases

ClinicalTrials.gov Identifier:

NCT01067443

First received: February 10, 2010

Last updated: March 9, 2011

Last verified: March 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	June 2011
Estimated Primary Completion Date:	June 2011 (Final data collection date for primary outcome measure)

No publications provided by Drugs for Neglected Diseases

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TP, Ellis S, Balasegaram M, Musa AM. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials. 2011 Jun 30;12:166.

To Top